BioJapan 2025

Richmond Pharmacology is excited to confirm our attendance at BioJapan 2025, Asia’s leading biotechnology partnering event, taking place in Yokohama from 8–10 October.

Representing Richmond at BioJapan 2025:

• Dr Jörg Täubel, Chief Executive Officer
• Dr Ulrike Lorch, Chief Medical Director
• Stephen Wilkinson, Business Development Manager
• Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
• Minoru Takada, Japanese Business Development Executive

We look forward to connecting with global partners, sharing insights, and exploring opportunities in:

• Early-phase trials for biologics and advanced therapies
• UK–Japan collaboration in gene editing and RNA medicines
• Regulatory strategy across Asia and Europe
• Bridging studies and multi-regional trial design
• Patient-centric and adaptive trial models

If you’re attending BioJapan 2025 and are looking to collaborate in translational research or clinical development, get in touch to arrange a meeting: info@richmondpharmacology.com

Learn more: BioJapan/ 再生医療JAPAN/ healthTECH JAPAN